CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Westin, Karin ^a,b   Buchhave, Peder ^a,b   Nielsen, Henrietta ^a   Minthon, Lennart ^a,b   Janciauskiene, Sabina ^c   Hansson, Oskar ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; EOTAXIN; EOTAXIN 3; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; TAU PROTEIN; BIOLOGICAL MARKER; CCL2 PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; BLOOD; CEREBROSPINAL FLUID; COHORT ANALYSIS; DEMOGRAPHY; FOLLOW UP; STATISTICAL MODEL;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHEMOKINE CCL2; COGNITION DISORDERS; COHORT STUDIES; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MILD COGNITIVE IMPAIRMENT;

EID: 84856383137     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030525     Document Type: Article

References (24)

1. Petersen RC, (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 183-194.
2. Blennow K, de Leon MJ, Zetterberg H, (2006) Alzheimer's disease. Lancet 368: 387-403.
3. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
4. Perry VH, Nicoll JA, Holmes C, (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6: 193-201.
5. Cameron B, Landreth GE, (2010) Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis 37: 503-509.
6. Maezawa I, Zimin PI, Wulff H, Jin LW, (2010) Amyloid-{beta} Protein Oligomer at Low Nanomolar Concentrations Activates Microglia and Induces Microglial Neurotoxicity. J Biol Chem 286: 3693-3706.
7. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, et al. (2009) Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 19: 392-398.
8. El Khoury J, Luster AD, (2008) Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci 29: 626-632.
9. Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, et al. (2005) Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol 166: 1475-1485.
10. Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, et al. (2009) CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One 4: e6197.
11. Blennow K, Hampel H, Weiner M, Zetterberg H, (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131-144.
12. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, et al. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-234.
13. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, et al. (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-393.
14. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403-413.
15. association AP (1987) Diagnostic and Statistical Manual of Mental Disorders Washington, DC American Psychiatric Association.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
17. Galimberti D, Schoonenboom N, Scarpini E, Scheltens P, (2003) Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol 53: 547-548.
18. Struthers M, Pasternak A, (2010) CCR2 antagonists. Curr Top Med Chem 10: 1278-1298.
19. Barrientos RM, Frank MG, Watkins LR, Maier SF, (2010) Memory impairments in healthy aging: Role of aging-induced microglial sensitization. Aging Dis 1: 212-231.
20. Schuitemaker A, van der Doef TF, Boellaard R, van der Flier WM, Yaqub M, et al. (2010) Microglial activation in healthy aging. Neurobiol Aging.
21. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, et al. (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73: 768-774.
22. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM, (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25: 8843-8853.
23. Sly LM, Krzesicki RF, Brashler JR, Buhl AE, McKinley DD, et al. (2001) Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res Bull 56: 581-588.
24. Herrup K, (2010) Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 30: 16755-16762.